https://www.selleckchem.com/pr....oducts/muvalaplin.ht
RESULTS Stride length (- 15%) and gait velocity (- 19%) were reduced, while stride (+ 7%) and stance time (+ 2%) were increased in patients with HD. However, parameters reflecting gait variability were substantially altered in HD patients (+ 17% stride length CV up to + 41% stride time CV with largest effect size) and showed strong correlations to TMS and TFC (0.416 ≤ rSp ≤ 0.69. Objective gait variability parameters correlated with disease stage based upon TFC. CONCLUSIONS Sensor-based gait variability parameters were identified a
Like
Comment
Share
